Brief: Herantis Pharma Announces Positive Topline Data From Clinical Trial

Herantis Pharma Oyj

25/10/2023 15:10

Oct 25 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * INSIDE INFORMATION: HERANTIS PHARMA ANNOUNCES POSITIVE
TOPLINE
DATA FROM THE PHASE 1A CLINICAL TRIAL OF HER-096, A DISEASE
MODIFYING THERAPEUTIC DEVELOPED FOR PARKINSON’S DISEASE
    * HER-096 PHASE 1A CLINICAL TRIAL MET PRIMARY AND SECONDARY
ENDPOINTS
    * SUBCUTANEOUS SINGLE DOSE INJECTIONS OF HER-096 HAD OVERALL
GOOD
SAFETY AND TOLERABILITY PROFILE
    * FAST UPTAKE OF HER-096 AFTER SUBCUTANEOUS INJECTION AND
DEMONSTRATED BLOOD-BRAIN BARRIER

Source text for Eikon:  ID:nMFN9drH3M 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))